At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 153 enrolled
Drug / intervention
Teneligliptin/Canagliflozindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long-term Administration Study of MT-2412 in Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating Teneligliptin/Canagliflozin for Type 2 Diabetes Mellitus. Completed, enrolled 153 participants across 6 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of co-administration of Teneligliptin (MP-513) and Canagliflozin (TA-7284) once daily for 52 weeks in Japanese patients with Type 2 diabetes mellitus who are receiving treatment with Teneligliptin and have inadequate glycemic control.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartAug 2014
First PostedAug 2014
Primary CompletionFeb 2016
TodayJul 2026
First PostedAug 20, 2014
Enrollment StartAug 1, 2014
Primary CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.9 years ago
Interventions
Teneligliptin/Canagliflozindrug
Co-administration of Teneligliptin and Canagliflozin orally once daily for 52 weeks.